These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9608318)

  • 21. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.
    Xynos ID; Tektonidou MG; Pikazis D; Sipsas NV
    Emerg Infect Dis; 2009 Jun; 15(6):956-9. PubMed ID: 19523302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future treatments of allergic diseases and asthma.
    Stirling RG; Chung KF
    Br Med Bull; 2000; 56(4):1037-53. PubMed ID: 11359636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New strategies against autoaggressive immune system. Is rheumatism to be healable soon?].
    Meissner T
    MMW Fortschr Med; 2003 Oct; 145(42):16. PubMed ID: 14655438
    [No Abstract]   [Full Text] [Related]  

  • 24. Advances in antibody engineering for rheumatic diseases.
    Schmid AS; Neri D
    Nat Rev Rheumatol; 2019 Apr; 15(4):197-207. PubMed ID: 30814691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting interleukin-6 in pediatric rheumatic diseases.
    De Benedetti F
    Curr Opin Rheumatol; 2009 Sep; 21(5):533-7. PubMed ID: 19593141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
    Cavalli G; Dinarello CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The production of chemotactic cytokines in an allogeneic response. The role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3.
    Lukacs NW; Kunkel SL; Burdick MD; Strieter RM
    Am J Pathol; 1993 Oct; 143(4):1179-88. PubMed ID: 7692733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregnancy appears difficult to obtain and TNF-alpha blockers cannot always be discontinued in women with rheumatic diseases.
    Gaujoux-Viala C; Eymard C; Dougados M; Gossec L
    Clin Exp Rheumatol; 2009; 27(6):1059. PubMed ID: 20149335
    [No Abstract]   [Full Text] [Related]  

  • 29. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
    Fenner H
    Z Rheumatol; 1995; 54(3):158-64. PubMed ID: 7660686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologics in the treatment of skin and rheumatologic diseases.
    Kahlenberg JM; Billi AC; Eyerich K; Gudjonsson JE
    J Allergy Clin Immunol; 2020 Apr; 145(4):1138-1141. PubMed ID: 32112793
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Novel B-cell directed strategies for the treatment of rheumatic diseases].
    Tarner IH
    Z Rheumatol; 2009 Jul; 68(5):380-9. PubMed ID: 19513729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future of monoclonal antibodies in solid organ transplantation.
    Cosimi AB
    Dig Dis Sci; 1995 Jan; 40(1):65-72. PubMed ID: 7821121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Feldmann M; Maini RN
    Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy.
    Williams RO; Marinova-Mutafchieva L; Feldmann M; Maini RN
    J Immunol; 2000 Dec; 165(12):7240-5. PubMed ID: 11120857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
    Peña-Sagredo JL; Fariñas MC; Perez-Zafrilla B; Cruz-Valenciano A; Crespo M; Joven-Ibañez B; Riera E; Manero-Ruiz FJ; Chalmeta I; Hernández MV; Rodríguez-Gómez M; Maíz O; López R; Cobo T; Pita J; Carmona L; Gonzalez-Gay MA;
    Clin Exp Rheumatol; 2009; 27(6):920-5. PubMed ID: 20149306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic therapy and pregnancy outcomes in women with rheumatic diseases.
    Vinet E; Pineau C; Gordon C; Clarke AE; Bernatsky S
    Arthritis Rheum; 2009 May; 61(5):587-92. PubMed ID: 19404999
    [No Abstract]   [Full Text] [Related]  

  • 40. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.